专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2008118356A2 BINDING PROTEINS, INCLUDING ANTIBODIES, ANTIBODY DERIVATIVES AND ANTIBODY FRAGMENTS, THAT SPECIFICALLY BIND CD154 AND USES THEREOF 审中-公开
标题翻译：结合蛋白，包括抗体，抗体衍生物和抗体片段，特异性结合CD154及其用途
公开(公告)号：WO2008118356A2
公开(公告)日：2008-10-02
申请号：PCT/US2008/003735
申请日：2008-03-21
申请人： BIOGEN IDEC MA INC. , UCB PHARMA S.A. , BURKLY, Linda C. , FERRANT-ORGETTAS, Janine L. , GARBER, Ellen A. , HSU, Yen-ming , SU, Lihe , TAYLOR, Frederick R. , ADAMS, Ralph , BROWN, Derek Thomas , POPPLEWELL, Andrew George , ROBINSON, Martyn Kim , SHOCK, Anthony , TYSON, Kerry Louise
发明人： BURKLY, Linda C. , FERRANT-ORGETTAS, Janine L. , GARBER, Ellen A. , HSU, Yen-ming , SU, Lihe , TAYLOR, Frederick R. , ADAMS, Ralph , BROWN, Derek Thomas , POPPLEWELL, Andrew George , ROBINSON, Martyn Kim , SHOCK, Anthony , TYSON, Kerry Louise
IPC分类号： C07K16/00
CPC分类号： C07K16/2875 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/24 , C07K2317/34 , C07K2317/40 , C07K2317/52 , C07K2317/55 , C07K2317/71 , C07K2317/734 , C07K2317/76 , C07K2317/92
摘要： This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.
摘要翻译：本发明提供了特异性结合CD154（CD40L）蛋白的结合蛋白，包括抗体，抗体衍生物和抗体片段。本发明还提供了嵌合的，人源化的或完全人源的抗体，抗体衍生物或抗体片段，其特异性结合人源化Fab片段的表位，所述人源化Fab片段包含根据SEQ ID NO：1的可变重链序列并且包含可变轻链序列根据SEQ ID NO：2特异性结合。相对于第二种抗CD154抗体，本发明的CD154结合蛋白可引起降低的效应子功能。本发明的CD154结合蛋白可用于诊断和治疗方法，例如用于治疗和预防包括由CD154-CD40相互作用介导的不希望的免疫应答的疾病在内的疾病。

2. 发明公开

EP2125894A2 BINDING PROTEINS, INCLUDING ANTIBODIES, ANTIBODY DERIVATIVES AND ANTIBODY FRAGMENTS, THAT SPECIFICALLY BIND CD154 AND USES THEREOF 有权转让
标题翻译：结合蛋白的抗体，抗体衍生物和抗体片段与特异性结合CD154及其用途
公开(公告)号：EP2125894A2
公开(公告)日：2009-12-02
申请号：EP08742182.2
申请日：2008-03-21
申请人： Biogen Idec MA, Inc. , UCB Pharma, S.A.
发明人： BURKLY, Linda C. , FERRANT-ORGETTAS, Janine L. , GARBER, Ellen A. , HSU, Yen-ming , SU, Lihe , TAYLOR, Frederick R. , ADAMS, Ralph , BROWN, Derek Thomas , POPPLEWELL, Andrew George , ROBINSON, Martyn Kim , SHOCK, Anthony , TYSON, Kerry Louise
IPC分类号： C07K16/28
CPC分类号： C07K16/2875 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/24 , C07K2317/34 , C07K2317/40 , C07K2317/52 , C07K2317/55 , C07K2317/71 , C07K2317/734 , C07K2317/76 , C07K2317/92
摘要： This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.
摘要翻译：本发明提供结合蛋白，包括抗体，抗体衍生物和抗体片段，并特异性结合CD154（CD40L）蛋白。本发明因此提供了一个嵌合的，人源化或完全的人抗体，抗体衍生物或抗体片段在表位做特异性结合到其上的人源化Fab片段包括雅丁于SEQ ID NO的可变重链序列：1和包含可变轻链序列根据SEQ ID NO：2特异性结合。 CD154结合本发明的蛋白可以引起相对于第二抗CD154抗体效应子功能降低。本发明的CD154结合蛋白可用于诊断和治疗方法，：例如在治疗和预防疾病，包括涉及thosethat不希望的免疫应答通过做了CD154-CD40相互作用介导有用的。

3. 发明申请

WO2006119062A2 EPITOPES 审中-公开
标题翻译：表位
公开(公告)号：WO2006119062A2
公开(公告)日：2006-11-09
申请号：PCT/US2006/016345
申请日：2006-04-28
申请人： UCB S.A. , AMGEN, INC. , LU, Hsieng, Sen , PASZTY, Christopher , ROBINSON, Martyn Kim , HENRY, Alistair James , HOFFMANN, Kelly Sue , LATHAM, John , LAWSON, Alastair , WINKLER, David , WINTERS, Aaron George
发明人： LU, Hsieng, Sen , PASZTY, Christopher , ROBINSON, Martyn Kim , HENRY, Alistair James , HOFFMANN, Kelly Sue , LATHAM, John , LAWSON, Alastair , WINKLER, David , WINTERS, Aaron George
IPC分类号： C07K14/51 , A61K38/10 , A61K38/17
CPC分类号： C07K16/18 , A61K2039/505 , C07K14/51 , C07K16/22 , C07K2317/24 , C07K2317/76 , C07K2317/92 , C12N15/63
摘要： Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided.
摘要翻译：提供了与硬骨素蛋白表位有关的组合物和方法，以及硬骨素结合剂，例如能结合硬化蛋白的抗体。

4. 发明申请

WO2016092101A1 ANTI-SCLEROSTIN ANTIBODIES AND THEIR USE TO TREAT BONE DISORDERS AS PART OF A REGIMEN 审中-公开
标题翻译：抗沙门氏菌抗体及其用作治疗骨质疏松症的一部分
公开(公告)号：WO2016092101A1
公开(公告)日：2016-06-16
申请号：PCT/EP2015/079496
申请日：2015-12-11
申请人： AMGEN INC. , UCB PHARMA S.A.
发明人： ROBINSON, Martyn Kim , OMINSKY, Michael Stuart , LI, Xiaodong , KE, Hua Zhu
IPC分类号： C07K16/22 , A61K39/00
CPC分类号： C07K16/22 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/54 , A61K2039/545 , A61P19/08 , A61P19/10 , C07K2317/76 , C07K2317/90 , C07K2317/94
摘要： The invention relates to the treatment of bone disorders. In particular, the invention provides an approach involving administration of a high initial dose or doses of an sclerostin antibody to bring about a rapid increase in bone formation, followed by administration of lowers doses of the antibody to give a sustained lower rate of bone formation after the initial burst of bone formation. The invention also provides an approach involving decreasing dosing frequency with such an antibody to control bone formation. The approaches may be used in particular in those subjects who would benefit most from such an initial rapid burst of bone formation. Examples of such subjects include subjects who have been recently diagnosed or are experiencing severe symptoms of the disorder, as well as those subjects who have been administered a different treatment for the bone disorder which is proving ineffective. The approaches may be used in combination with each other.
摘要翻译：本发明涉及骨病的治疗。特别地，本发明提供了一种方法，其包括施用高初始剂量或剂量的硬化蛋白抗体以引起骨形成的快速增加，随后施用较低剂量的抗体，以在持续较低的骨形成速率之后产生持续较低的骨形成速率最初的骨骼形成爆发。本发明还提供了一种涉及用这种抗体降低给药频率以控制骨形成的方法。这些方法可以特别用于从这种初始的骨形成快速爆发中受益最大的受试者。这些受试者的实例包括最近被诊断或正在经历该病症的严重症状的受试者，以及被证明无效的骨病症的不同治疗对象。这些方法可以彼此组合使用。

5. 发明申请

WO2014006100A1 TREATMENT FOR BONE DISEASES 审中-公开
标题翻译：治疗骨质疏松
公开(公告)号：WO2014006100A1
公开(公告)日：2014-01-09
申请号：PCT/EP2013/064052
申请日：2013-07-03
申请人： UCB PHARMA S.A.
发明人： ROBINSON, Martyn Kim
IPC分类号： A61K39/395 , C07K16/22
CPC分类号： A61K39/3955 , A61K33/42 , A61K45/06 , A61K2039/505 , C07K16/18 , C07K16/22 , C07K2317/94
摘要： The invention relates to the treatment of bone disorders. In particular, the invention is directed to the use of a dosing holiday to help overcome the resistance to anti-sclerostin antibodies which develops over time when a plurality of doses of antibody are given to a subject. By giving the subject to be treated such a dosing holiday, the subject may subsequently display an increased response to a subsequent dose of the anti-sclerostin antibody. The subject may be given multiple cycles of a batch of at least two doses of anti-sclerostin antibody and a dosing holiday. In some instances, the subject may be monitored to help determine when to give the dosing holiday. Further, the subject may be given a different treatment for the bone disorder during the dosing holiday from the anti-sclerostin antibody.
摘要翻译：本发明涉及骨病的治疗。特别地，本发明涉及使用剂量假期来帮助克服当将多种剂量的抗体给予受试者时随时间发展的抗硬化蛋白抗体的抗性。通过给予受治疗的这样的给药假期，受试者随后可以显示对后续剂量的抗硬皮素抗体的增加的应答。可以给予受试者一批至少两剂量的抗硬化蛋白酶抗体和给药假期的多个周期。在某些情况下，可以监控受试者，以帮助确定何时给予假期。此外，可以从抗硬化蛋白酶抗体给药假期期间对受试者进行不同的治疗。

6. 发明公开

EP3626267A1 TREATMENT FOR BONE DISEASES 审中-公开
公开(公告)号：EP3626267A1
公开(公告)日：2020-03-25
申请号：EP19205429.4
申请日：2013-07-03
申请人： UCB Pharma, S.A.
发明人： ROBINSON, Martyn Kim
IPC分类号： A61K39/395 , C07K16/22
摘要： The invention relates to the treatment of bone disorders. In particular, the invention is directed to the use of a dosing holiday to help overcome the resistance to 5 anti-sclerostin antibodies which develops over time when a plurality of doses of antibody are given to a subject. By giving the subject to be treated such a dosing holiday, the subject may subsequently display an increased response to a subsequent dose of the anti-sclerostin antibody. The subject may be given multiple cycles of a batch of at least two doses of anti-sclerostin antibody and a dosing holiday. In some 10 instances, the subject may be monitored to help determine when to give the dosing holiday. Further, the subject may be given a different treatment for the bone disorder during the dosing holiday from the anti-sclerostin antibody.

7. 发明公开

EP3230315A1 ANTI-SCLEROSTIN ANTIBODIES AND THEIR USE TO TREAT BONE DISORDERS AS PART OF A REGIMEN 审中-公开
标题翻译：抗SCLEROSTIN抗体及其作为治疗方案治疗骨质疏松症的用途
公开(公告)号：EP3230315A1
公开(公告)日：2017-10-18
申请号：EP15816412.9
申请日：2015-12-11
申请人： Amgen Inc. , UCB Pharma S.A.
发明人： ROBINSON, Martyn Kim , OMINSKY, Michael Stuart , LI, Xiaodong , KE, Hua Zhu
IPC分类号： C07K16/22 , A61K39/00
CPC分类号： C07K16/22 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/54 , A61K2039/545 , A61P19/08 , A61P19/10 , C07K2317/76 , C07K2317/90 , C07K2317/94
摘要： The invention relates to the treatment of bone disorders. In particular, the invention provides an approach involving administration of a high initial dose or doses of an sclerostin antibody to bring about a rapid increase in bone formation, followed by administration of lowers doses of the antibody to give a sustained lower rate of bone formation after the initial burst of bone formation. The invention also provides an approach involving decreasing dosing frequency with such an antibody to control bone formation. The approaches may be used in particular in those subjects who would benefit most from such an initial rapid burst of bone formation. Examples of such subjects include subjects who have been recently diagnosed or are experiencing severe symptoms of the disorder, as well as those subjects who have been administered a different treatment for the bone disorder which is proving ineffective. The approaches may be used in combination with each other.
摘要翻译：本发明涉及骨疾病的治疗。具体而言，本发明提供了一种方法，其涉及施用高初始剂量或多个剂量的硬骨素抗体以引起骨形成的快速增加，接着施用较低剂量的抗体以在骨形成后持续降低骨形成速率最初爆发的骨骼形成。本发明还提供了一种涉及用这种抗体控制骨形成来降低给药频率的方法。这些方法可以特别用于那些将从这种最初的骨形成快速爆发中获益最多的受试者。这些受试者的实例包括最近已被诊断或正在经历该病症的严重症状的受试者，以及那些已经被证明无效的已被施用不同骨治疗方法的受试者。这些方法可以相互结合使用。

8. 发明公开

EP1891100A2 SCLEROSTIN EPITOPES 审中-公开
标题翻译：硬化表位
公开(公告)号：EP1891100A2
公开(公告)日：2008-02-27
申请号：EP06751835.7
申请日：2006-04-28
申请人： UCB Pharma S.A. , Amgen Inc.
发明人： LU, Hsieng, Sen , PASZTY, Christopher , ROBINSON, Martyn Kim , HENRY, Alistair James , HOFFMANN, Kelly Sue , LATHAM, John , LAWSON, Alastair , WINKLER, David , WINTERS, Aaron George
IPC分类号： C07K14/51 , A61K38/10 , A61K38/17
CPC分类号： C07K16/18 , A61K2039/505 , C07K14/51 , C07K16/22 , C07K2317/24 , C07K2317/76 , C07K2317/92 , C12N15/63
摘要： Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided.

9. 发明公开

EP3985015A1 SCLEROSTIN BINDING AGENTS 审中-实审
公开(公告)号：EP3985015A1
公开(公告)日：2022-04-20
申请号：EP21188463.0
申请日：2006-04-28
申请人： UCB Pharma S.A. , Amgen, Inc
发明人： PASZTY, Christopher , ROBINSON, Martyn Kim , GRAHAM, Kevin , HENRY, Alistair James , HOFFMAN, Kelly Sue , LATHAM, John , LAWSON, Alastair , LU, Hsieng Sen , POPPLEWELL, Andy , SHEN, Wenyan , WINKLER, David , WINTERS, Aaron George
IPC分类号： C07K14/51 , C07K16/18
摘要： Compositions and methods relating to epitopes of sclerostin protein, and sclerostin-binding agents, such as antibodies capable of binding to sclerostin, are provided.

10. 发明公开

EP3670528A1 SCLEROSTIN BINDING AGENTS 有权
公开(公告)号：EP3670528A1
公开(公告)日：2020-06-24
申请号：EP19211623.4
申请日：2006-04-28
申请人： UCB Pharma S.A. , Amgen, Inc
发明人： PASZTY, Christopher , ROBINSON, Martyn Kim , GRAHAM, Kevin , HENRY, Alistair James , HOFFMAN, Kelly Sue , LATHAM, John , LAWSON, Alastair , LU, Hsieng Sen , POPPLEWELL, Andy , SHEN, Wenyan , WINKLER, David , WINTERS, Aaron George
IPC分类号： C07K14/51 , C07K16/18
摘要： Compositions and methods relating to epitopes of sclerostin protein, and sclerostin-binding agents, such as antibodies capable of binding to sclerostin, are provided.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式